Elucidation of the Impact of Radiation-induced Intravascular Oxidative Stress on Cancer Metastasis

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K15806
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Shizuoka Cancer Center Research Institute (2023); Kyoto University (2021-2022)
• Principal Investigator: Inoue Minoru 静岡県立静岡がんセンター(研究所), その他部局等, 研究員 (20826010)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: がん / 放射線治療 / 血清アルブミン / フェロトーシス / 脂質過酸化

Outline of Final Research Achievements

This study focused on the redox state of cysteine-34 (Cys34) in serum albumin (HSA) as an indicator of vascular oxidative stress and its impact on the prognosis of differentiated thyroid carcinoma (DTC). Through a cohort study involving DTC patients, it was revealed that patients with higher concentrations of the reduced form of HSA-Cys34 (HMA) had longer progression-free survival compared to those with lower concentrations. Additionally, in vitro experiments demonstrated that HMA induces ferroptosis in DTC cells. The redox state of HSA-Cys34 is thus a promising prognostic factor and therapeutic target in DTC, potentially contributing to the development of personalized treatment strategies.

Free Research Field

放射線治療

Academic Significance and Societal Importance of the Research Achievements

血清アルブミン（HSA）システイン34（Cys34）の酸化還元状態が、分化型甲状腺がん（DTC）細胞に脂質過酸化を介したフェロトーシス誘導に関与することを明らかにした本研究は、今後、フェロトーシスの新規誘導メカニズム解明およびその応用に関する基礎研究の進展という学術的意義を有すると考えられる。また、本研究ではDTC症例においても、還元型のHSA-Cys34（HMA）が無再発生存期間延長と関連することを明らかにしたため、HSA-Cys34の還元を促進する治療法の開発等を通じて、DTC患者の予後改善に寄与し得るという社会的意義を有している。